Jade Biosciences (JBIO) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.86
- EPS estimate
- −$0.43
- EPS surprise
- −98.48%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 13, 2025
Jade Biosciences' most recent results in the table are for Q2 2025, reported on August 13, 2025. The company posted a loss of $0.86 per share, wider than the −$0.43 estimate by 98.48%. No revenue was reported and no revenue estimate was given.
Jade Biosciences has reported a loss in every quarter in the table. The per-share figures before Q2 2025 are on a very different scale, which makes direct comparison unreliable. Losses ran between $6.65 and $30.10 per share from 2022 through Q1 2025, and an extreme $833.00 per share in Q2 2021. The year-earlier Q2 2024 loss was $30.10. Across the 17 quarters shown, the company missed the EPS estimate 16 times and matched it once, in Q3 2021, never beating it. No revenue appears anywhere in the table.
The table has not been updated since the Q2 2025 report. In earlier years, results for the third quarter came between November 12 and November 15. Later quarters will show the loss per share on the new scale, giving a basis for comparison that the older figures do not provide.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 13, 2025 | −$0.43 | −$0.86 | −98.48% | $0.00 | SEC |
| Q1 2025 | Apr 25, 2025 | −$6.03 | −$12.10 | −100.83% | $0.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$6.57 | −$6.65 | −1.17% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$16.36 | −$19.60 | −19.79% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$28.78 | −$30.10 | −4.58% | $0.00 | SEC |
| Q1 2024 | May 13, 2024 | −$26.76 | −$29.05 | −8.56% | $0.00 | SEC |
| Q4 2023 | Mar 25, 2024 | −$23.76 | −$25.90 | −9.00% | $0.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$24.24 | −$24.85 | −2.50% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$24.36 | −$26.60 | −9.20% | $0.00 | SEC |
| Q1 2023 | May 15, 2023 | −$21.00 | −$23.45 | −11.68% | $0.00 | SEC |
| Q4 2022 | Mar 29, 2023 | −$21.09 | −$21.35 | −1.22% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$17.44 | −$19.60 | −12.37% | $0.00 | SEC |
| Q2 2022 | Aug 15, 2022 | −$15.58 | −$17.15 | −10.11% | $0.00 | — |
| Q1 2022 | May 16, 2022 | −$9.74 | −$15.75 | −61.68% | $0.00 | — |
| Q4 2021 | Mar 30, 2022 | −$11.00 | −$11.90 | −8.20% | $0.00 | — |
| Q3 2021 | Nov 15, 2021 | −$9.10 | −$9.10 | +0.00% | $0.00 | — |
| Q2 2021 | Aug 16, 2021 | −$5.48 | −$833.00 | −15091.58% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Jade Biosciences (JBIO) last report earnings?
Jade Biosciences last reported on Aug 13, 2025, covering fiscal Q2 2025.
Did JBIO beat earnings estimates?
No. Jade Biosciences reported EPS of −$0.86 for Q2 2025 against a −$0.43 estimate — a 98.48% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.